U.S.-based investment fund Mason Capital said on Monday it had sent a letter to Spain's stock market regulator CNMV demanding ...

The Michael J. Fox Foundation for Parkinson’s Research has partnered with Grifols, a global healthcare company, to identify ...

Grifols, a global healthcare company and leading producer of plasma-derived medicines, today announced it has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to ...

Spanish drugmaker Grifols has been awarded a $21 million grant from the Michael J Fox Foundation to support a pilot study to ...

Grifols has filed for US approval of a new drug for rare bleeding disorder acquired fibrinogen deficiency (AFD), which ...

Grifols has received a grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) to identify plasma-based ...

"We urge the CNMV to consider the benefits to all Grifols shareholders from improved disclosure," Mason Capital said. As global markets navigate a mixed economic landscape marked by declining ...

Mason Capital Management LLC’s Kenneth M Garschina has called the Spanish regulator’s attention to Grifols SA’s “severe lack of disclosure” as he tries to push for a board reshuffle.

Flat Footed today sent a letter to the Grifols Board of Directors. The full text of the letter follows: Dear Mr. Glanzmann, Flat Footed LLC is the investment manager for FF Hybrid LP, Flat Footed ...

US short seller Gotham City Research asked a judge in New York to dismiss a lawsuit accusing it of conspiring to drive down shares in Grifols SA. The drug maker’s market capitalization has ...

The unique plasma assets serve as the foundation of the Chronos-PD program, driving advanced research at Grifols subsidiary Alkahest, which is leading the initiative given its specialization in the ...